Selective and mixed endothelin receptor antagonism in cardiovascular disease

Trends in Pharmacological Sciences

Volumn 28, Issue 11, 2007, Pages 573-579

  Dhaun, Neeraj ^a,c   Pollock, David M ^b   Goddard, Jane ^a,c   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CLAZOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; SITAXSENTAN;

ARTERIOLE; ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG MEGADOSE; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HYPERTENSION; INOTROPISM; KIDNEY BLOOD VESSEL; KIDNEY CORTEX; KIDNEY MEDULLA; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; PULMONARY ARTERY; PULMONARY HYPERTENSION; RENAL ARTERY; REVIEW; SCLERODERMA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; MODELS, BIOLOGICAL; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; THIOPHENES;

EID: 35648934472     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.10.002     Document Type: Review

References (72)

1. Davenport A.P., and Maguire J.J. Endothelin. Handb. Exp. Pharmacol. 176 pt 1 (2006) 295-329
2. Haynes W.G., and Webb D.J. The endothelin family of peptides: local hormones with diverse roles in health and disease?. Clin. Sci. 84 (1993) 485-500
3. Yanagisawa M., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
4. Schiffrin E.L. Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens. 14 (2001) 83S-89S
5. Davenport A.P., et al. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J. Cardiovasc. Pharmacol. 22 (1993) S22-S25
6. DeNucci G., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U. S. A 85 (1988) 9797-9800
7. Dhaun N., et al. The endothelin system and its antagonism in chronic kidney disease. J. Am. Soc. Nephrol. 17 (2006) 943-955
8. Gasic S., et al. Regional haemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to overall disposal of the peptide. J. Cardiovasc. Pharmacol. 19 (1992) 176-180
9. Dupuis J., et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94 (1996) 1278-1284
10. Attina T., et al. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91 (2005) 825-831
11. Available at. http://www.iuphar-db.org/GPCR/ReceptorDisplayForward?receptorID=2263
12. Lahav R., et al. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A 96 (1999) 11496-11500
13. D'Alonzo G.E., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115 (1991) 343-349
14. Rubin L.J., et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346 (2002) 896-903
15. Motte S., et al. Endothelin receptor antagonists. Pharmacol. Ther. 110 (2006) 386-414
16. Ivy D., et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am. J. Physiol. 280 (2001) L1040-L1048
17. Ivy D.D., et al. Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus. Am. J. Physiol. 279 (2000) L758-L765
18. Sato K., et al. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am. J. Physiol. 269 (1995) L668-L672
19. Eddahibi S., et al. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am. J. Physiol. 268 (1995) H828-H835
20. Tilton R.G., et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm. Pharmacol. Ther. 13 (2000) 87-97
21. Chen S.J., et al. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J. Cardiovasc. Pharmacol. 29 (1997) 713-725
22. Barst R.J., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169 (2004) 441-447
23. Barst R.J., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 47 (2006) 2049-2056
24. Krum H., et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med. 338 (1998) 784-790
25. Hocher B., et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. 23 (2000) 19-26
26. Davie N., et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 165 (2002) 398-405
27. Nishida M., et al. Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats. Eur. J. Pharmacol. 496 (2004) 159-165
28. Nishida M., et al. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension. J. Cardiovasc. Pharmacol. 44 (2004) 187-191
29. Sakai S., et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93 (1996) 1214-1222
30. Kobayashi T., et al. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am. J. Physiol. 276 (1999) H1197-H1206
31. Pieske B., et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 99 (1999) 1802-1809
32. Mulder P., et al. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation 102 (2000) 491-493
33. Ohnishi M., et al. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. Cardiovasc. Res. 39 (1998) 617-624
34. Cowburn P.J., et al. Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur. J. Heart Fail. 7 (2005) 37-42
35. Battistini, B. et al. (2006) Profile of Past and Current Clinical Triaqls Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug. Soc Exp Biol Med
36. Anand I., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 327-354
37. Luscher T.F., et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106 (2002) 2666-2672
38. Rossi G.P., et al. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 99 (1999) 1147-1155
39. Cardillo C., et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33 (1999) 753-758
40. Martin P., et al. Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension 39 (2002) 821-824
41. Goddard J., et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109 (2004) 1186-1193
42. Nakov R., et al. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am. J. Hypertens. 15 (2002) 583-589
43. Morita S., et al. Immunoreactive endothelin in human kidney. Ann. Clin. Biochem. 28 (1991) 267-271
44. Karet F.E., and Davenport A.P. Localization of endothelin peptides in human kidney. Kidney Int. 49 (1996) 382-387
45. Kuc R., and Davenport A.P. Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J. Cardiovasc. Pharmacol. 44 (2004) S224-S226
46. Nabokov A., et al. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol. Dial. Transplant. 11 (1996) 514-520
47. Wolf S.C., et al. Protective effects of endothelin antagonists in chronic renal failure. Nephrol. Dial. Transplant. 14 (1999) 29-30
48. Shimizu T., et al. Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats. Eur. J. Pharmacol. 381 (1999) 39-49
49. Pernow J., et al. Effect of endothelin-1 on regional vascular resistance in the pig. J. Cardiovasc. Pharmacol. 13 (1989) S205-S206
50. Denton K.M., et al. Effect of endothelin-1 on regional kidney blood flow and renal arteriole calibre in rabbits. Clin. Exp. Pharmacol. Physiol. 31 (2004) 494-501
51. Rubinstein I., et al. Differential effect of endothelin-1 on renal regional blood flow: role of nitric oxide. J. Cardiovasc. Pharmacol. 26 (1995) S208-S210
52. Evans R.G., et al. Effects of ET(A) - and ET(B)-receptor antagonists on regional kidney blood flow, and responses to intravenous endothelin-1, in anaesthetized rabbits. J. Hypertens. 19 (2001) 1789-1799
53. Ding S.S., et al. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J. Cardiovasc. Pharmacol. 42 (2003) 48-54
54. Hunley T.E., et al. Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J. Am. Soc. Nephrol. 5 (1995) 1718-1723
55. Available at. http://www.clinicaltrials.gov/ct/show/NCT00120328
56. Inscho E.W., et al. ET(A) and ET(B) receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br. J. Pharmacol. 146 (2005) 1019-1026
57. Goddard J., et al. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J. Am. Soc. Nephrol. 15 (2004) 2601-2610
58. Ihling C., et al. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 104 (2001) 864-869
59. Kowala M.C., et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am. J. Pathol. 146 (1995) 819-826
60. Barton M., et al. Endothelin ET(A) receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U. S. A 95 (1998) 14367-14372
61. Best P.J.M., et al. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolaemia. Circulation 99 (1999) 1747-1752
62. Babaei S., et al. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc. Res. 48 (2000) 158-167
63. d'Uscio L.V., et al. Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. Cardiovasc. Res. 53 (2002) 487-495
64. Halcox J.P., et al. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ. Res. 89 (2001) 969-976
65. Halcox J.P., et al. Endogenous endothelin in human coronary vascular function. Differential contribution of endothelin receptor types A and B. Hypertension 49 (2007) 1-8
66. Andresen J., et al. Endothelial influences on cerebrovascular tone. J. Appl. Physiol. 100 (2006) 318-327
67. Matsuo Y., et al. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 32 (2001) 2143-2148
68. Petrov T., and Rafols J.A. Acute alterations of endothelin-1 and iNOS expression and control of the brain microcirculation after head trauma. Neurol. Res. 23 (2001) 139-143
69. Chow M., et al. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 51 (2002) 1333-1341
70. Macdonald R.L., et al. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat. Clin. Pract. Neurol. 3 (2007) 256-263
71. Plato C.F., and Garvin J.L. Nitric oxide, endothelin and nephron transport: potential interactions. Clin. Exp. Pharmacol. Physiol. 26 (1999) 262-268
72. Honing M.L., et al. Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J. Am. Soc. Nephrol. 11 (2000) 1498-1504